{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:57:23Z","timestamp":1781697443324,"version":"3.54.5"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203308"],"award-info":[{"award-number":["NIHR203308"]}],"id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","award":["UL2006-4168\/CKTO 2006-04"],"award-info":[{"award-number":["UL2006-4168\/CKTO 2006-04"]}],"id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"publisher","award":["2021-1\/13404"],"award-info":[{"award-number":["2021-1\/13404"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR300650"],"award-info":[{"award-number":["NIHR300650"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.modpat.2026.101000","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:16:48Z","timestamp":1775841408000},"page":"101000","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Desert Immune Phenotype in Endometrial Carcinoma: A Distinct Subgroup With Poor Prognosis and Targetable Mutations"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0253-1182","authenticated-orcid":false,"given":"Merve","family":"Kaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence H.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Oosting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie E.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma J.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda R.","family":"Mileshkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lois","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"de Bruyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Jobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith R.","family":"Kroep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carien L.","family":"Creutzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanda","family":"Horeweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"L\u00e9on-Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Parra-Herran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent T.H.B.M.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa R.","family":"Nucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6881-8437","authenticated-orcid":false,"given":"Tjalling","family":"Bosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.modpat.2026.101000_bib7","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.annonc.2024.02.006","article-title":"Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer","volume":"35","author":"Bogani","year":"2024","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.modpat.2026.101000_bib8","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/07357907.2021.2012188","article-title":"PD-1\/PD-L1 inhibitors monotherapy for the treatment of endometrial cancer: meta-analysis and systematic review","volume":"40","author":"Dai","year":"2022","journal-title":"Cancer Invest"},{"key":"10.1016\/j.modpat.2026.101000_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102701","article-title":"Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis","volume":"125","author":"Bartoletti","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.modpat.2026.101000_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101759","article-title":"Efficacy of PD-(L)1 inhibition in the treatment of endometrial cancer across molecular classes: a systematic review and meta-analysis","volume":"35","author":"Kaya","year":"2025","journal-title":"Int J Gynecol Cancer"},{"issue":"7637","key":"10.1016\/j.modpat.2026.101000_bib11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.modpat.2026.101000_bib12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.modpat.2026.101000_bib13","doi-asserted-by":"crossref","first-page":"5668","DOI":"10.1038\/s41467-021-25962-0","article-title":"Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer","volume":"12","author":"Hammerl","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.modpat.2026.101000_bib14","article-title":"HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma","volume":"9","author":"Wang","year":"2019","journal-title":"Sci Rep"},{"issue":"7528","key":"10.1016\/j.modpat.2026.101000_bib15","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.modpat.2026.101000_bib16","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.modpat.2026.101000_bib17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s00262-024-03919-8","article-title":"Understanding the impact of spatial immunophenotypes on the survival of endometrial cancer patients through the ProMisE classification","volume":"74","author":"Hattori","year":"2025","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.modpat.2026.101000_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100624","article-title":"Spatial cancer-immune phenotypes predict shorter recurrence-free survival in the no specific molecular profile molecular subtype of endometrial carcinoma","volume":"38","author":"de Biase","year":"2025","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.modpat.2026.101000_bib19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial","volume":"19","author":"de Boer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.modpat.2026.101000_bib20","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41416-023-02141-0","article-title":"Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry","volume":"128","author":"Vermij","year":"2023","journal-title":"Br J Cancer"},{"issue":"29","key":"10.1016\/j.modpat.2026.101000_bib21","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.modpat.2026.101000_bib22","series-title":"Female Genital Tumours","year":"2020"},{"issue":"2","key":"10.1016\/j.modpat.2026.101000_bib23","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1264565","article-title":"Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition","volume":"6","author":"Eggink","year":"2017","journal-title":"Oncoimmunology"},{"issue":"14","key":"10.1016\/j.modpat.2026.101000_bib24","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1158\/1078-0432.CCR-15-0057","article-title":"POLE proofreading mutations elicit an antitumor immune response in endometrial cancer","volume":"21","author":"van Gool","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.modpat.2026.101000_bib25","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamaoncol.2015.2151","article-title":"Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1","volume":"1","author":"Howitt","year":"2015","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.modpat.2026.101000_bib26","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1158\/1078-0432.CCR-18-3241","article-title":"Molecular subtype not immune response drives outcomes in endometrial carcinoma","volume":"25","author":"Talhouk","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.modpat.2026.101000_bib27","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1158\/2326-6066.CIR-20-0149","article-title":"Prognostic integrated image-based immune and molecular profiling in early-stage endometrial cancer","volume":"8","author":"Horeweg","year":"2020","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"10.1016\/j.modpat.2026.101000_bib28","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/path.6012","article-title":"The association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patients","volume":"258","author":"L\u00f3pez-Janeiro","year":"2022","journal-title":"J Pathol"},{"issue":"9","key":"10.1016\/j.modpat.2026.101000_bib29","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/s41379-022-01066-y","article-title":"Genomic landscape of endometrial carcinomas of no specific molecular profile","volume":"35","author":"Momeni-Boroujeni","year":"2022","journal-title":"Mod Pathol"},{"issue":"44","key":"10.1016\/j.modpat.2026.101000_bib30","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000040186","article-title":"Pancancer analysis of the interactions between CTNNB1 and infiltrating immune cell populations","volume":"103","author":"Xu","year":"2024","journal-title":"Medicine (Baltimore)"},{"issue":"7559","key":"10.1016\/j.modpat.2026.101000_bib31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.modpat.2026.101000_bib32","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00404-021-06385-0","article-title":"Prognostic significance of CTNNB1 mutation in early stage endometrial carcinoma: a systematic review and meta-analysis","volume":"306","author":"Travaglino","year":"2022","journal-title":"Arch Gynecol Obstet"},{"issue":"16","key":"10.1016\/j.modpat.2026.101000_bib33","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.modpat.2026.101000_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-23016-z","article-title":"Direct AKT activation in tumor-infiltrating lymphocytes markedly increases interferon-\u03b3 (IFN-\u03b3) for the regression of tumors resistant to PD-1 checkpoint blockade","volume":"12","author":"Santinon","year":"2022","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.modpat.2026.101000_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004703","article-title":"Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR\/MSI-H gastrointestinal cancer","volume":"10","author":"Wang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.modpat.2026.101000_bib36","doi-asserted-by":"crossref","first-page":"5599","DOI":"10.1200\/JCO.2025.43.16_suppl.5599","article-title":"E7386 study 102: global dose-expansion cohort of E7386 + lenvatinib (LEN) in patients (pts) with advanced endometrial cancer (aEC) that progressed on platinum-based chemotherapy (chemo) and an anti-PD-(L)1 immunotherapy (IO)","volume":"43","author":"Lee","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2026.101000_bib37","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12943-025-02363-1","article-title":"Wnt\/\u03b2-catenin mediated signaling pathways in cancer: recent advances, and applications in cancer therapy","volume":"24","author":"Wu","year":"2025","journal-title":"Mol Cancer"},{"issue":"7","key":"10.1016\/j.modpat.2026.101000_bib38","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1245\/s10434-016-5173-8","article-title":"Interobserver agreement between pathologists assessing tumor-infiltrating lymphocytes (TILs) in breast cancer using methodology proposed by the International TILs Working Group","volume":"23","author":"Swisher","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.modpat.2026.101000_bib45","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.modpat.2026.101000_bib39","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/PAP.0000000000000161","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv Anat Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2026.101000_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-018-4825-8","article-title":"Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study","volume":"171","author":"O'Loughlin","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.modpat.2026.101000_bib41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41523-020-0156-0","article-title":"Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer","volume":"6","author":"Kos","year":"2020","journal-title":"NPJ Breast Cancer"},{"issue":"10","key":"10.1016\/j.modpat.2026.101000_bib42","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.annonc.2021.07.007","article-title":"The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition","volume":"32","author":"Loi","year":"2021","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.modpat.2026.101000_bib43","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/PAS.0000000000001409","article-title":"Assessment of tumor-infiltrating lymphocytes using International TILs Working Group (ITWG) system is a strong predictor of overall survival in colorectal carcinoma: a study of 1034 patients","volume":"44","author":"Fuchs","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"10.1016\/j.modpat.2026.101000_bib44","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.18906","article-title":"Pathologist-read vs AI-driven assessment of tumor-infiltrating lymphocytes in melanoma","volume":"8","author":"Aung","year":"2025","journal-title":"JAMA Netw Open"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226000438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226000438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:33:14Z","timestamp":1781695994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395226000438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0893395226000438"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2026.101000","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Desert Immune Phenotype in Endometrial Carcinoma: A Distinct Subgroup With Poor Prognosis and Targetable Mutations","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2026.101000","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}],"article-number":"101000"}}